Alternative HPV vaccination schedules in Latin America

In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3...

Full description

Bibliographic Details
Main Authors: Claudia Robles, María de la Luz Hernández, Maribel Almonte
Format: Article
Language:English
Published: Instituto Nacional de Salud Pública 2018-12-01
Series:Salud Pública de México
Subjects:
Online Access:http://www.saludpublica.mx/index.php/spm/article/view/9810
id doaj-a20f18f944ca42d0bce4e678bad537b7
record_format Article
spelling doaj-a20f18f944ca42d0bce4e678bad537b72020-11-24T21:09:31ZengInstituto Nacional de Salud PúblicaSalud Pública de México0036-36341606-79162018-12-01606, nov-dic69370210.21149/981016607Alternative HPV vaccination schedules in Latin AmericaClaudia Robles0María de la Luz Hernández1Maribel Almonte21.- International Agency for Research on Cancer (IARC/WHO), Lyon, France 2.-Institut Catala d'Oncologia, Barcelona, SpainInternational Agency for Research on Cancer (IARC/WHO), Lyon, FranceInternational Agency for Research on Cancer (IARC/WHO), Lyon, FranceIn 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clini­cal efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed.http://www.saludpublica.mx/index.php/spm/article/view/9810VPH vaccinationvaccination schedulesnumber of vaccine doses
collection DOAJ
language English
format Article
sources DOAJ
author Claudia Robles
María de la Luz Hernández
Maribel Almonte
spellingShingle Claudia Robles
María de la Luz Hernández
Maribel Almonte
Alternative HPV vaccination schedules in Latin America
Salud Pública de México
VPH vaccination
vaccination schedules
number of vaccine doses
author_facet Claudia Robles
María de la Luz Hernández
Maribel Almonte
author_sort Claudia Robles
title Alternative HPV vaccination schedules in Latin America
title_short Alternative HPV vaccination schedules in Latin America
title_full Alternative HPV vaccination schedules in Latin America
title_fullStr Alternative HPV vaccination schedules in Latin America
title_full_unstemmed Alternative HPV vaccination schedules in Latin America
title_sort alternative hpv vaccination schedules in latin america
publisher Instituto Nacional de Salud Pública
series Salud Pública de México
issn 0036-3634
1606-7916
publishDate 2018-12-01
description In 2008, the first HPV vaccination program in Latin America started in Panama, targeting girls aged 10-11 years with a 3-dose vaccine schedule, an initiative that was to be followed by other Latin American countries after local feasibility and population acceptability evaluations were completed. A 3-dose vaccine regimen over six months was originally chosen for HPV vaccines, copying the Hepatitis B vaccine schedule (0, 1-2, 6 months). Alternative vaccine schedules have been proposed afterwards based on: i) noninferior immunogenicity or immune response levels compared to those at which clini­cal efficacy has been proven (i.e., those observed in a 3-dose HPV vaccine schedule in women aged 15-26), and, ii) proven efficacy in clinical trials and/or effectiveness among women who were provided less than three doses due to a lack of adherence to a 3-dose vaccine schedule. In 2014, based on the available evidence and the potential increase in coverage by expansion of vaccination target groups, particularly in low and middle income countries (LMIC), the World Health Organization recommended a 2-dose schedule with at least a 6-month interval between doses for females up to 15 years of age and a 3-dose schedule for older women. More recently, it has been suggested that 1-dose HPV vaccination schemes may provide enough protection against HPV infection and may speed up the introduction of HPV vaccination in LMIC, where most needed.
topic VPH vaccination
vaccination schedules
number of vaccine doses
url http://www.saludpublica.mx/index.php/spm/article/view/9810
work_keys_str_mv AT claudiarobles alternativehpvvaccinationschedulesinlatinamerica
AT mariadelaluzhernandez alternativehpvvaccinationschedulesinlatinamerica
AT maribelalmonte alternativehpvvaccinationschedulesinlatinamerica
_version_ 1716758147701407744